Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CRBN encodes a protein related to the Lon protease protein family. Additionally we are shipping Cereblon Kits (22) and Cereblon Proteins (11) and many more products for this protein.
Showing 10 out of 49 products:
Human Polyclonal CRBN Primary Antibody for ICC, IF - ABIN4300387
Gandhi, Mendy, Waldman, Chen, Rychak, Miller, Gaidarova, Ren, Wang, Breider, Carmel, Mahmoudi, Jackson, Abbasian, Cathers, Schafer, Daniel, Lopez-Girona, Thakurta, Chopra: Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. in British journal of haematology 2014
Show all 3 Pubmed References
Human Polyclonal CRBN Primary Antibody for WB - ABIN526543
Charoenfuprasert, Yang, Lee, Chao, Chu, Lai, Hsu, Chang, Chen, Chen, Chang, Leu, Shih: Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. in Oncogene 2011
Show all 3 Pubmed References
mitochondrially expressed CRBN exhibited protease activity, and was induced by oxidative stress.
we identify Rabex-5 (show RABGEF1 Antibodies) as a Immunomodulatory drugs (IMiDs) target molecule that functions to restrain TLR activated auto-immune promoting pathways. We propose that release of Rabex-5 (show RABGEF1 Antibodies) from complex with Cereblon enables the suppression of immune responses, contributing to the antiinflammatory properties of IMiDs.
We sequenced CRBN-thalidomide binding region in 38 thalidomide embryopathy individuals and 136 Brazilians without congenital anomalies, and performed in silico analyses. Eight variants were identified, seven intronic and one in 3'UTR (show UTS2R Antibodies).
These findings thus contribute to a growing list of ID disorders caused by CRBN mutations, broaden the spectrum of phenotypes attributable to Autosomal-recessive non-syndromic intellectual disability (ARNS-ID)and provide new insight into genotype-phenotype correlations between CRBN mutations and the aetiology of ARNS-ID.
CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach.
Plasmablast differentiation, whether induced by BAFF (show TNFSF13B Antibodies) or CD40L (show CD40LG Antibodies), is prevented by modulation of CRBN activity with CC-220, which induces degradation of the B cell differentiation factors Aiolos (show IKZF3 Antibodies) and Ikaros (show IKZF1 Antibodies). Downregulation of these B cell differentiation processes by CC-220 modulation of CRBN provides a new therapeutic approach to treating B cell-mediated pathology in SLE.
High CRBN expression is associated with multiple myeloma.
CRBN negatively regulates TLR4 (show TLR4 Antibodies) signaling via attenuation of TRAF6 (show TRAF6 Antibodies) and TAB2 (show TAB2 Antibodies) ubiquitination.
Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS (show NRAS Antibodies), and/or BRAF (show BRAF Antibodies) (72%), as well as TP53 (show TP53 Antibodies) (26%), CRBN (12%), and CRBN pathway genes (10%) was observed.
results suggest that CRBN binds to Ikaros (show IKZF1 Antibodies) via its N-terminal region and regulates transcriptional activities of Ikaros (show IKZF1 Antibodies) and its downstream target, enkephalin
Collectively, our data suggested that CRBN is a potential treatment option against diabetes-induced osteolytic bone disease.
Data show that cereblon (CRBN) limits CD4 (show CD4 Antibodies)(+) T-cell activation via epigenetic regulation of Kv1.3 (show KCNA3 Antibodies) potassium channel (show KCNAB2 Antibodies) (Kv1.3 (show KCNA3 Antibodies)) expression.
CRBN is involved in the activation of PERK (show EIF2AK3 Antibodies) and the Ire1 (show ERN1 Antibodies) pathway of the unfolded protein response.CRBN plays a role in cellular stress signaling, including the unfolded protein response, by controlling the activity of AMPK (show PRKAA1 Antibodies).
results of this study suggest a plausible mechanism for CRBN involvement in higher brain function in humans, and they may help explain how a specific mutation in CRBN can affect the cognitive ability of patients
Found significantly smaller infarct sizes and less fibrosis in the hearts of CRBN KO mice than in those of WT mice. Apoptosis was also significantly reduced in the KO mice compared with that in WT mice.
findings suggest that crbn-/- mice exhibit selective HPC-dependent deficits in associative learning.
CRBN directly interacts with the alpha1 subunit of AMP-activated protein kinase (AMPK (show PRKAA2 Antibodies) alpha1) and inhibits the activation of AMPK (show PRKAA1 Antibodies) activation.
These results imply that Nrf2 (show NFE2L2 Antibodies) stimulates CRBN gene transcription under hypoxia-reoxygenation conditions in neuronal cells.
This gene encodes a protein related to the Lon protease protein family. In rodents and other mammals this gene product is found in the cytoplasm localized with a calcium channel membrane protein, and is thought to play a role in brain development. Mutations in this gene are associated with autosomal recessive nonsyndromic mental retardation. Multiple transcript variants encoding different isoforms have been found for this gene.
, protein cereblon-like
, protein x 0001
, novel lethal
, protein PiL
, Protein cereblon